Literature DB >> 33322370

An Experience of Donor Lymphocyte Infusion after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.

Tahereh Rostami1, Azadeh Kiumarsi1.   

Abstract

Allogeneic hematopoietic stem-cell transplantation is a well-known curative treatment for patients with chronic granulomatous disease. We present our experiment regarding ten patients with chronic granulomatous disease who underwent a reduced intensity conditioning regimen consisting of melfalan, fludarabine, and antithymocyte globulin. Donor lymphocyte infusion was used in three representative patients who developed mixed donor chimerism. After at least 2 years of median follow-up, 8 of the 10 patients are alive and well.

Entities:  

Keywords:  CGD; allogeneic hematopoietic stem cell transplantation; chronic granulomatous disease; donor lymphocyte infusion; reduced-intensity conditioning

Year:  2020        PMID: 33322370      PMCID: PMC7768393          DOI: 10.3390/pediatric12030030

Source DB:  PubMed          Journal:  Pediatr Rep        ISSN: 2036-749X


  17 in total

Review 1.  Chronic granulomatous disease - conventional treatment vs. hematopoietic stem cell transplantation: an update.

Authors:  Anders Åhlin; Anders Fasth
Journal:  Curr Opin Hematol       Date:  2015-01       Impact factor: 3.284

2.  Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease.

Authors:  Bhakti Mehta; Kris Mahadeo; Neena Kapoor; Hisham Abdel-Azim
Journal:  Pediatr Transplant       Date:  2015-04-02

3.  Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.

Authors:  M Sykes; A Eisenthal; D H Sachs
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

4.  Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).

Authors:  S T Ildstad; S M Wren; J A Bluestone; S A Barbieri; D Stephany; D H Sachs
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

5.  Quantitative nitroblue tetrazolium test in chronic granulomatous disease.

Authors:  R L Baehner; D G Nathan
Journal:  N Engl J Med       Date:  1968-05-02       Impact factor: 91.245

6.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.

Authors:  A J Barrett; D Mavroudis; J Tisdale; J Molldrem; E Clave; C Dunbar; M Cottler-Fox; S Phang; C Carter; P Okunnieff; N S Young; E J Read
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

7.  Bone marrow transplantation in chronic granulomatous disease.

Authors:  N Kamani; C S August; S D Douglas; E Burkey; A Etzioni; H W Lischner
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

8.  Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.

Authors:  Benjamin Oshrine; Megan Morsheimer; Jennifer Heimall; Nancy Bunin
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167

9.  Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease.

Authors:  R S Hill; F B Petersen; R Storb; F R Appelbaum; K Doney; S Dahlberg; R Ramberg; E D Thomas
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

10.  Donor lymphocyte infusion at unstable mixed chimerism in an allogeneic BMT recipient for chronic granulomatous disease.

Authors:  S Akioka; H Itoh; I Ueda; Y Matsumoto; H Iwami; K Tsunamoto; S Hibi; S Todo; T Sawada; S Imashuku
Journal:  Bone Marrow Transplant       Date:  1998-09       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.